Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
DERMA SCIENCES, INC. (DSCI)
|
Add to portfolio |
|
|
|
| Price: |
$7.00
| | Metrics |
| OS: |
28.3
|
M
| |
-9
|
% ROE
|
| Market cap: |
$198
|
M
| |
47
|
% ROIC
|
|
Net cash:
|
$56.4
|
M
| |
$2.00
|
per share
|
|
EV:
|
$141
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$5.9
|
M
| |
23.9
|
x EV/EBITDA
|
|
EBIT
|
$2.5
|
M
| |
55.9
|
x EV/EBIT
|
| EPS |
$0.17
| |
41.1
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 84.5 | 83.7 | 79.7 | 72.6 | 62.6 | 56.5 | 48.5 | 50.2 |
| Revenue growth | 0.9% | 5.1% | 9.7% | 16.0% | 10.9% | 16.4% | -3.3% | 47.1% |
| Cost of goods sold | 51.7 | 53.6 | 50.3 | 47.5 | 45.2 | 39.9 | 33.5 | 35.3 |
| Gross profit | 32.7 | 30.1 | 29.4 | 25.1 | 17.4 | 16.5 | 15.1 | 14.9 |
| Gross margin | 38.8% | 36.0% | 36.9% | 34.6% | 27.8% | 29.3% | 31.0% | 29.7% |
| Selling, general and administrative | 51.4 | 50.8 | 41.9 | 32.5 | 21.2 | 17.9 | 15.1 | 17.2 |
| Research and development | 0.8 | 0.4 | | 7.1 | 1.1 | 0.3 | 0.4 | 0.7 |
| EBITA | -16.5 | -18.1 | -9.7 | -12.2 | -2.3 | 0.0 | -0.5 | -1.5 |
| EBITA margin | -19.6% | -21.6% | -12.2% | -16.8% | -3.6% | 0.0% | -1.0% | -3.0% |
| Amortization of intangibles | 3.0 | 3.1 | 2.8 | 2.3 | 1.6 | 1.7 | | 1.4 |
| EBIT | -19.5 | -21.2 | -12.6 | -14.5 | -3.8 | -1.7 | -0.5 | -2.9 |
| EBIT margin | -23.1% | -25.3% | -15.8% | -19.9% | -6.1% | -3.0% | -1.0% | -5.9% |
| Pre-tax income | -22.6 | -21.0 | -12.4 | -14.4 | -4.3 | -2.0 | -1.1 | -3.9 |
| Income taxes | -2.2 | -0.2 | 0.2 | -2.4 | 0.1 | 0.4 | 0.2 | 0.1 |
| Tax rate | 9.9% | 0.7% | | 16.4% | | | | |
| Net income | -38.1 | -39.8 | -24.0 | -12.1 | -4.3 | -2.4 | -1.3 | -4.0 |
| Net margin | -45.1% | -47.5% | -30.1% | -16.6% | -6.9% | -4.3% | -2.6% | -7.9% |
| |
| Diluted EPS | ($0.79) | ($0.85) | ($0.73) | ($0.97) | ($0.49) | ($0.39) | ($0.25) | ($0.82) |
| Shares outstanding (diluted) | 25.7 | 24.6 | 17.1 | 12.5 | 8.8 | 6.3 | 5.0 | 4.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|